로사이돌프만병(RDD) 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 유형별(고전적 로사이돌프만병(RDD), 절외 로사이돌프만병(RDD)), 시술 유형별, 최종사용자별, 지역별, 경쟁별(2020-2030년)
Rosai-Dorfman Disease Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Classic Rosai-Dorfman disease, Extranodal Rosai-Dorfman disease), By Procedure Type, By End User, By Region and Competition, 2020-2030F
세계 로사이돌프만병(RDD) 시장은 2024년 6억 4,705만 달러로 평가되었고, 2030년에는 9억 6,266만 달러에 달할 것으로 예상되며, 예측 기간 동안 6.82%의 연평균 성장률(CAGR)을 보일 것으로 예측됩니다.
이 시장은 헬스케어 산업에서 전문적이고 중요한 분야로, 다량의 림프절 부종을 동반한 유비동 조직구증(SHML)으로 알려진 희귀한 비악성 질환의 진단, 치료 및 진행 중인 연구에 초점을 맞추었습니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모 : 2024년 |
6억 4,705만 달러 |
| 시장 규모 : 2030년 |
9억 6,266만 달러 |
| CAGR : 2025-2030년 |
6.82% |
| 급성장 부문 |
병원 및 클리닉 |
| 최대 시장 |
북미 |
RDD는 주로 림프절 내에 조직구(백혈구의 일종)가 과도하게 증식 및 축적되는 것이 특징이지만, 다른 조직과 장기에도 영향을 미칠 수 있습니다. 희귀질환임에도 불구하고 전 세계적으로 인지도가 높아지고, 진단 기술의 발전과 효과적인 치료 전략의 추구로 인해 시장 성장이 가속화되고 있습니다.
주요 촉진요인
발병률 상승과 진단 기술의 발전
로자이-도르프만병은 추정 유병률이 20만 명당 1명, 미국에서는 연간 약 100명의 신규 환자가 보고되는 등 여전히 드문 질환이지만, 진단 능력의 향상으로 전 세계적으로 질병을 확인하는 사례가 증가하고 있습니다. 영상진단 기술, 병리조직학, 분자진단학의 혁신은 RDD 진단의 정확성과 신속성을 향상시키고, 보고 건수 증가에 기여하며, 표적 치료 개입에 대한 수요를 촉진하고 있습니다.
이러한 인식 증가는 특별한 진단 도구와 치료법 개발을 위한 연구개발에 박차를 가하고 있습니다. 일부 RDD 환자에서 BRAF-V600E와 같은 유전자 돌연변이 발견을 포함한 최근 발견은 정밀의료와 맞춤 치료 전략의 새로운 기회를 열어주었습니다. 그 결과, 제약회사와 의료 서비스 제공업체들은 RDD의 임상적, 생물학적 특성에 특화된 치료법에 투자하고 있습니다.
이 시장에는 진단 분석, 영상 시스템, 의약품, 지지 요법 솔루션 등 다양한 제품이 있습니다. 제약사, 학계, 임상 제공업체 간의 협력은 연구를 진행하고, 질병 메커니즘을 규명하고, 잠재적 바이오마커를 탐색하고, 혁신적인 치료법을 개발하는 데 있어 매우 중요합니다.
주요 과제
낮은 질병 유병률과 낮은 인지도
RDD는 희귀질환이기 때문에 임상 증상이 다른 흔한 질환과 유사해 오진이나 진단 지연으로 이어지는 경우가 많으며, 무증상 림프절 종대부터 광범위한 장기 병변까지 다양한 증상을 나타낼 수 있어 적시 발견을 더욱 복잡하게 만듭니다. 광범위한 장기 병변에 이르기까지 다양한 증상을 보일 수 있어 적시에 발견하는 것이 더욱 복잡합니다.
RDD는 임상적으로 접하는 빈도가 낮기 때문에 의사들 사이에서도 일반적으로 잘 알려져 있지 않아 신속하고 정확한 진단을 방해하고 있습니다. 또한, RDD에 대한 인식 부족은 RDD에 특화된 연구에 대한 자금 지원 및 투자에 영향을 미쳐 진단 및 치료법 혁신의 진전을 제한하고 있습니다. 이러한 투자 부족은 효과적이고 표적화된 중재법 개발에 어려움을 초래하고, 이 질환의 병태생리에 대한 폭넓은 이해를 방해하고 있습니다.
주요 시장 동향
면역조직화학 및 분자 프로파일링 채택
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 로사이돌프만병(RDD) 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 병형별(고전적(절성) 로사이돌프만병(RDD), 절외성 로사이돌프만병(RDD))
- 시술 유형별(진단, 치료)
- 최종사용자별(병원 및 진료소, 외래 진료 센터, 기타)
- 기업별(2024년)
- 지역별
- 시장 맵
제6장 북미의 로사이돌프만병(RDD) 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 북미 : 국가별 분석
제7장 유럽의 로사이돌프만병(RDD) 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 로사이돌프만병(RDD) 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 아시아태평양 : 국가별 분석
제9장 남미의 로사이돌프만병(RDD) 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 로사이돌프만병(RDD) 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 중동 및 아프리카 : 국가별 분석
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트(UAE)
제11장 시장 역학
제12장 시장 동향과 발전
제13장 PESTEL 분석
제14장 Porter의 Five Forces 분석
- 업계내 경쟁
- 신규 참여 가능성
- 공급업체의 힘
- 고객의 힘
- 대체품의 위협
제15장 경쟁 구도
- Koninklijke Philips N.V.
- GE HealthCare
- Canon Inc
- Siemens Healthineers
- SternMed GmbH
- Jubilant Cadista Pharmaceuticals Inc
- LGM Pharma
- Henan Lihua Pharmaceutical Co., Ltd
- Niksan Pharmaceutical
- Sandoz Canada Inc
제16장 전략적 제안
제17장 리서치사에 대해 & 면책사항
LSH
Global Rosai-Dorfman Disease (RDD) market was valued at USD 647.05 million in 2024 and is projected to reach USD 962.66 million by 2030, expanding at a compound annual growth rate (CAGR) of 6.82% over the forecast period. This market represents a specialized yet vital segment of the healthcare industry, focusing on the diagnosis, treatment, and ongoing research of Rosai-Dorfman Disease-a rare, non-malignant disorder also known as sinus histiocytosis with massive lymphadenopathy (SHML).
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 647.05 Million |
| Market Size 2030 | USD 962.66 Million |
| CAGR 2025-2030 | 6.82% |
| Fastest Growing Segment | Hospitals & Clinics |
| Largest Market | North America |
RDD is characterized by the excessive proliferation and accumulation of histiocytes-a type of white blood cell-primarily within lymph nodes, though it may also affect other tissues and organs. Despite its rarity, growing global awareness, advancements in diagnostic technologies, and the pursuit of effective treatment strategies have accelerated market growth.
Key Drivers
Rising Incidence and Diagnostic Advancements
While Rosai-Dorfman Disease remains an uncommon condition-with an estimated prevalence of 1 in 200,000 individuals and approximately 100 new cases reported annually in the United States-enhanced diagnostic capabilities have led to increased identification of the disease globally. Innovations in imaging techniques, histopathology, and molecular diagnostics have improved the accuracy and timeliness of RDD diagnoses, contributing to a higher reported case volume and driving demand for targeted therapeutic interventions.
This growing recognition has fueled research and development activities aimed at creating specialized diagnostic tools and treatments. Recent discoveries, including the identification of genetic mutations such as BRAF-V600E in select RDD patients, have opened new opportunities for precision medicine and personalized treatment strategies. As a result, pharmaceutical firms and healthcare providers are investing in therapies tailored specifically to the clinical and biological characteristics of RDD.
The market spans a broad range of offerings including diagnostic assays, imaging systems, pharmaceuticals, and supportive care solutions. Collaborative efforts among pharmaceutical companies, academic institutions, and clinical providers are crucial in advancing research, uncovering disease mechanisms, exploring potential biomarkers, and developing innovative treatments.
Key Challenges
Low Disease Prevalence and Limited Awareness
A significant barrier to market development is the exceptionally low prevalence of RDD, compounded by limited awareness among healthcare professionals. The rarity of the condition often leads to misdiagnosis or delayed diagnosis, as its clinical presentation may mimic other, more common diseases. RDD can manifest with a wide spectrum of symptoms, from asymptomatic lymph node enlargement to extensive organ involvement, further complicating timely detection.
Infrequent clinical encounters with RDD contribute to a general unfamiliarity among physicians, hindering prompt and accurate diagnosis. Additionally, the lack of widespread awareness impacts funding and investment in RDD-specific research, limiting advancements in diagnostic and therapeutic innovations. This underinvestment challenges the development of effective, targeted interventions and impedes the broader understanding of the disease's pathophysiology.
Key Market Trends
Adoption of Immunohistochemistry and Molecular Profiling
The market is witnessing a paradigm shift toward precision diagnostics, underscored by the increasing use of immunohistochemistry (IHC) and molecular profiling. These technologies are becoming standard in identifying and confirming RDD cases with greater accuracy. IHC techniques enable the detection of disease-specific protein markers such as S100 and CD68, facilitating differentiation from other histiocytic and lymphoproliferative disorders.
Simultaneously, molecular profiling-through platforms such as next-generation sequencing (NGS)-is uncovering recurrent mutations (e.g., KRAS, MAP2K1) associated with RDD pathogenesis. These insights are paving the way for personalized therapeutic approaches, particularly for patients with refractory or recurrent disease.
As molecular diagnostic tools become more accessible and cost-effective, their adoption is expanding across both developed and emerging healthcare markets. Institutions are integrating these technologies into clinical practice, not only improving diagnostic precision but also enhancing patient monitoring and prognosis assessment.
Key Market Players
- Koninklijke Philips N.V.
- GE HealthCare
- Canon Inc
- Siemens Healthineers
- SternMed GmbH
- Jubilant Cadista Pharmaceuticals Inc
- LGM Pharma
- Henan Lihua Pharmaceutical Co., Ltd
- Niksan Pharmaceutical
- Sandoz Canada Inc
Report Scope:
In this report, the Global Rosai-Dorfman Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Global Rosai-Dorfman Disease Market, By Type:
- Classic (nodal) Rosai-Dorfman disease
- Extranodal Rosai-Dorfman disease
Global Rosai-Dorfman Disease Market, By Route of Administration:
- Oral
- Parenteral
- Sublingual
- Nasal
Global Rosai-Dorfman Disease Market, By End User:
- Hospitals & Clinics
- Ambulatory Care Centres
- Others
Global Rosai-Dorfman Disease Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Rosai-Dorfman Disease Market.
Available Customizations:
Global Rosai-Dorfman Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Rosai-Dorfman Disease Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Type (Classic (nodal) Rosai-Dorfman disease, Extranodal Rosai-Dorfman disease)
- 5.2.2. By Procedure Type (Diagnosis, Treatment)
- 5.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centres, Others)
- 5.2.4. By Company (2024)
- 5.2.5. By Region
- 5.3. Market Map
6. North America Rosai-Dorfman Disease Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Procedure Type
- 6.2.3. By End User
- 6.2.4. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Rosai-Dorfman Disease Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Type
- 6.3.1.2.2. By Procedure Type
- 6.3.1.2.3. By End User
- 6.3.2. Mexico Rosai-Dorfman Disease Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Type
- 6.3.2.2.2. By Procedure Type
- 6.3.2.2.3. By End User
- 6.3.3. Canada Rosai-Dorfman Disease Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Type
- 6.3.3.2.2. By Procedure Type
- 6.3.3.2.3. By End User
7. Europe Rosai-Dorfman Disease Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Procedure Type
- 7.2.3. By End User
- 7.2.4. By Age Group
- 7.2.5. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. France Rosai-Dorfman Disease Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Type
- 7.3.1.2.2. By Procedure Type
- 7.3.1.2.3. By End User
- 7.3.2. Germany Rosai-Dorfman Disease Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Type
- 7.3.2.2.2. By Procedure Type
- 7.3.2.2.3. By End User
- 7.3.3. United Kingdom Rosai-Dorfman Disease Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Type
- 7.3.3.2.2. By Procedure Type
- 7.3.3.2.3. By End User
- 7.3.4. Italy Rosai-Dorfman Disease Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Type
- 7.3.4.2.2. By Procedure Type
- 7.3.4.2.3. By End User
- 7.3.5. Spain Rosai-Dorfman Disease Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Type
- 7.3.5.2.2. By Procedure Type
- 7.3.5.2.3. By End User
8. Asia-Pacific Rosai-Dorfman Disease Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Procedure Type
- 8.2.3. By End User
- 8.2.4. By Age Group
- 8.2.5. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Rosai-Dorfman Disease Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Type
- 8.3.1.2.2. By Procedure Type
- 8.3.1.2.3. By End User
- 8.3.2. India Rosai-Dorfman Disease Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Type
- 8.3.2.2.2. By Procedure Type
- 8.3.2.2.3. By End User
- 8.3.3. South Korea Rosai-Dorfman Disease Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Type
- 8.3.3.2.2. By Procedure Type
- 8.3.3.2.3. By End User
- 8.3.4. Japan Rosai-Dorfman Disease Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Type
- 8.3.4.2.2. By Procedure Type
- 8.3.4.2.3. By End User
- 8.3.5. Australia Rosai-Dorfman Disease Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Type
- 8.3.5.2.2. By Procedure Type
- 8.3.5.2.3. By End User
9. South America Rosai-Dorfman Disease Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Procedure Type
- 9.2.3. By End User
- 9.2.4. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Rosai-Dorfman Disease Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Type
- 9.3.1.2.2. By Procedure Type
- 9.3.1.2.3. By End User
- 9.3.2. Argentina Rosai-Dorfman Disease Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Type
- 9.3.2.2.2. By Procedure Type
- 9.3.2.2.3. By End User
- 9.3.3. Colombia Rosai-Dorfman Disease Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Type
- 9.3.3.2.2. By Procedure Type
- 9.3.3.2.3. By End User
10. Middle East and Africa Rosai-Dorfman Disease Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Procedure Type
- 10.2.3. By End User
- 10.2.4. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Rosai-Dorfman Disease Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Type
- 10.3.1.2.2. By Procedure Type
- 10.3.1.2.3. By End User
- 10.3.2. Saudi Arabia Rosai-Dorfman Disease Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Type
- 10.3.2.2.2. By Procedure Type
- 10.3.2.2.3. By End User
- 10.3.3. UAE Rosai-Dorfman Disease Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Type
- 10.3.3.2.2. By Procedure Type
- 10.3.3.2.3. By End User
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions
13. PESTLE Analysis
14. Porter's Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Product
15. Competitive Landscape
- 15.1. Koninklijke Philips N.V.
- 15.1.1. Business Overview
- 15.1.2. Company Snapshot
- 15.1.3. Products & Services
- 15.1.4. Financials (As Reported)
- 15.1.5. Recent Developments
- 15.1.6. Key Personnel Details
- 15.1.7. SWOT Analysis
- 15.2. GE HealthCare
- 15.3. Canon Inc
- 15.4. Siemens Healthineers
- 15.5. SternMed GmbH
- 15.6. Jubilant Cadista Pharmaceuticals Inc
- 15.7. LGM Pharma
- 15.8. Henan Lihua Pharmaceutical Co., Ltd
- 15.9. Niksan Pharmaceutical
- 15.10. Sandoz Canada Inc
16. Strategic Recommendations
17. About Us & Disclaimer
